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Abstract: Colorectal cancer is one of the most prevalent cancers in the world. Patients  
in advanced stages often develop metastases that require chemotherapy and usually show  
a poor response, have a low survival rate and develop considerable toxicity with adverse 
symptoms. Gene therapy may act as an adjuvant therapy in attempts to destroy the tumor 
without affecting normal host tissue. The bacteriophage E gene has demonstrated significant 
antitumor activity in several cancers, but without any tumor-specific activity. The use of 
tumor-specific promoters may help to direct the expression of therapeutic genes so they act 
against specific cancer cells. We used the carcinoembryonic antigen promoter (CEA) to 
direct E gene expression (pCEA-E) towards colon cancer cells. pCEA-E induced a high cell 
growth inhibition of human HTC-116 colon adenocarcinoma and mouse MC-38 colon 
cancer cells in comparison to normal human CCD18co colon cells, which have practically 
undetectable levels of CEA. In addition, in vivo analyses of mice bearing tumors induced 
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using MC-38 cells showed a significant decrease in tumor volume after pCEA-E treatment 
and a low level of Ki-67 in relation to untreated tumors. These results suggest that the CEA 
promoter is an excellent candidate for directing E gene expression specifically toward colon 
cancer cells. 
Keywords: carcinoma embryonic antigen; colorectal cancer; E gene; suicide gene therapy; 
promoter tissue specific 
 
1. Introduction 
Colon cancer, along with breast and lung cancer, is one of the most prevalent cancers in the world [1]. 
While in early stages, colon cancer is characterized by a good prognosis, in more advanced, metastatic 
stages, the five-year survival rate is only 10%. Approximately 25% of all colon cancer patients reach 
this stage and are principally treated with 5-fluorouracil (5-FU) alone or a combination of oxaliplatin 
(FOLFOX, a combo of oxaliplatin, 5-FU and leucovorin), irinotecan (FOLFIRI, a combo of irinotecan, 
5-FU and leucovorin), angiogenesis inhibitors and/or epidermal growth factor receptor inhibitors [2]. 
However, the results from current treatments are poor and may be accompanied by tissue damage.  
In this context, gene therapy tries to modify or destroy the tumor cell uniquely from within, without 
causing damage to any other tissues. Recent studies have investigated several aspects of gene therapy 
related to cancer treatment; one of these approaches is suicide gene therapy [3], which may enhance  
the potential of the drugs typically used to treat cancer [4], including colon cancer [5,6]. 
Classic systems of suicide gene therapy rely on the administration of a prodrug. The prodrug is 
catalyzed by suicide enzymes to produce a toxic substance capable of inducing cancer cell death. The most 
representative enzyme of this therapeutic strategy, thymidine kinase (TK), has been assayed in clinical 
trials against gliomas [7], prostate cancer [8] and hepatocellular carcinoma [9], among others. However, 
the conversion of a non-toxic prodrug into toxic metabolites and the bioavailability of the activated drug 
severely limit the system’s efficacy. These causes of treatment failure are currently overcome by using 
genes that encode for cytotoxic proteins, which have a direct antitumor action. Some of these genes are 
taken from non-eukaryotic organisms, such as viruses, bacteria and plants [4,10–12]. We have recently 
shown how the toxic E gene from the bacteriophage ϕX174, which codes for a 91-amino acid membrane 
protein with lytic function [6,13,14], significantly decreased colon cancer cell proliferation, inducing 
mitochondrial apoptosis. Analysis of the mechanism suggests the formation of a “transmembrane pore” 
through which the cell loses cytoplasmic content. Interestingly, this gene did not need a prodrug to 
induce cell death [15]. The use of tumor-specific promoters that are overexpressed in cancer could drive 
transcription of these proteins known to be selectively active in tumor cells, thus obtaining a therapeutic 
system with a more specifically localized activity. Recently, survivin promoter [16], human telomerase 
reverse transcriptase promoter [17] and epithelial cell adhesion molecule (EpCAM) promoter [18] have 
been assayed to delivery TK or CD (cytosine deaminase) genes in cancer cells. 
Carcinoma embryonic antigen (CEA) is an oncofetal tumor marker, which is overexpressed in over 
90% of colorectal cancer cells, but not in normal colon cells [19–21]. In addition, CEA can be detected 
in 70% of colorectal cancer diagnoses [22,23]. Michl et al. [24] discovered significantly elevated CEA 
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serum concentrations in patients in the final stages of the pathology; hence, they used CEA as a prognosis 
marker. Shibutani et al. [22] corroborated the utility of CEA levels for predicting the prognosis and also 
for monitoring recurrence and metastasis after potentially curative surgery in patients with stage II 
colorectal cancer. Wang et al. [25] concluded that high levels of tissue mRNA expression and CEA 
serum are associated with the incidence and progression of colorectal cancer, while Patel et al. [26] used 
CEA as a clinical and pathologic prognostic marker of local recurrence and overall survival after 
resection. Thus, the CEA promoter has been used in gene therapy to direct the expression of therapeutic 
genes toward CEA-positive cancer cells [16]. In fact, Zhang et al. [27] demonstrated the selective 
expression, under the transcriptional control of the CEA promoter, of the cytosine deaminase (CD) 
enzyme in colon cancer cells. 
The aim of this study was to investigate the activity of the E gene, a toxic gene for colon cancer cells, 
under CEA promoter transcriptional control, which is frequently overexpressed in this type of tumor cell. 
We analyzed different colon cancer cell lines in order to select those with differential CEA expression. 
Colon cancer cells were then transfected in vitro to assess the anti-proliferative effect of the E gene under 
the influence of the CEA promoter. We also analyzed the in vivo cytotoxicity of the pCEA-E gene  
to demonstrate its activity with respect to tumor growth and mouse survival rates. Furthermore,  
we analyzed the toxicity of this new gene therapy and its effect over proliferation rates. 
2. Results 
2.1. Transcriptional Activity of CEA Promoter 
CEA activity was detected in all seven colon cancer cell lines by luciferase assay. Human HTC-116, 
CACO-2, RKO colon adenocarcinoma cell lines and mouse MC-38 colon cancer cells showed high 
levels of luciferase expression, whereas human HT-29, T-84 and SW480 adenocarcinoma cell lines 
showed a low degree of luciferase expression. Specifically, HTC-116 showed the highest level of 
luciferase among all of the colorectal cancer cells, while T-84 cells presented the least expression of 
cancer cells. In contrast, normal intestinal epithelial CCD18co cells demonstrated the lowest levels of 
CEA activity (Figure 1). 
2.2. In Vitro Inhibition of Cell Growth by pCEA-E 
To analyze the E gene antiproliferative effect under CEA promoter transcriptional control, we selected 
the colon cancer cell lines with the highest (HTC-116) and lowest (T-84) CEA promoter activity, as well 
as normal CCD18co cells, which presented practically null CEA promoter activity. Furthermore, we 
analyzed MC-38 cells in order to carry out in vivo experiments. As shown in Figure 2A, HTC-116 cells 
transfected with the E gene showed a significant and time-dependent decrease in growth. Cell growth 
inhibition was 15%, 31% and 48% at 24, 48 and 72 h, respectively, after transfection and in relation  
to control cells. Similar results were observed for the MC-38 colon cancer cells, which were also 
characterized by strong CEA promoter activity (Figure 2C). By contrast, T-84 cells with weak CEA 
promoter activity showed proliferation inhibition levels of only 4%, 8.5% and 13.5% at 24, 48 and 72 h 
after transfection, respectively. CCD118co colon cells with no CEA promoter activity showed  
an insignificant change in the % of proliferation (see “control”).  




Figure 1. Transcriptional activity of CEA. Human CACO-2, HT29, HCT-116, SW480, 
RKO and T-84 colon adenocarcinoma cell lines,  mice MC-38 colon cancer cell line, and the 
normal human colon CCD18co cell line Cells were co-transfected with luciferase expression 
vectors pPGL2/CEA or pGL2 and the Renilla expression vector CMV/Renilla. Luciferase 
activity of each transfection was normalized by the Renilla reading. Luciferase activity is 
represented by the ratio of the specific promoter over the activity of pGL2. Data represent 
the mean value of three replicates ± the standard error of the mean (SEM). 
 
Figure 2. Effect of pCEA-E on cell proliferation. Cells from cell lines HTC-116 (A),  
T-84 (B), MC-38 (C) and CCD18co (D) were transfected with pCEA-E to determine 
proliferation rate modulation after 24, 48 and 72 h. Data represent the mean value of three 
replicates ± the standard error of the mean (SEM). 
Expression of E protein in cells transfected with pCEA-E was confirmed using the anti-V5-FITC 
antibody. Positive staining was detected in HTC-116 and MC-38 cells, but not in T-84 and CCD118co 
cells (Figure 3). 




Figure 3. Subcellular localization of E/V5 fusion protein. Recombinant E protein (E-V5) 
was detected using anti-V5-FITC antibody (green) in HTC-116 (a) and MC-38 (b). No stain 
was observed in T-84 (c) and CCD18co (d) cells following pCEA-E treatment. Twenty-four 
hours after transfection, the fluorescence pattern was dotted and located in the cell 
cytoplasm. Cell nuclei were stained by DAPI (blue). Magnification: 40×. 
2.3. In Vivo Tumor Growth Inhibition and Survival Analysis 
As Figure 4 shows, intratumoral treatment with pCEA-E produced significant reductions in tumor 
volumes after 33 days. Specifically, pCEA-E was able to induce a 36% tumor volume reduction in 
comparison to the control (p < 0.05). pCEA-LacZ treatment, on the other hand, did not bring about any 
modifications in tumor growth rates, yielding similar results to those observed in the untreated mouse 
group. Nevertheless, although pCEA-E treatment produced reductions in tumor volumes, it failed to 
increase mouse survival rates compared to the untreated control group (data not shown). 
 
Figure 4. Tumor growth inhibition induced by pCEA-E. Treatment with pCEA-E induced a 
significant reduction in tumor volume at the end of the study period (33 days) in comparison 
with the growth of pCEA-LacZ-treated or untreated tumors (control) (p < 0.05). Data 
represent the mean value ± SEM. 
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2.4. In Vivo Toxicity 
Mouse body mass was monitored throughout the treatment in order to determine the in vivo toxicity 
of the pCEA-E transfected gene. Both mice treated with pCEA-E or pCEA-LacZ revealed no significant 
weight loss in comparison to the control group, suggesting that neither of the plasmid administrations 
induced any toxicity (Figure 5). 
 
Figure 5. Weight evolution after pCEA-E treatment. The weights of mice bearing 
subcutaneous MC-38 tumors and treated with pCEA-E were measured. pCEA-E-treated  
mice experienced a similar weight evolution to that of pCEA-LacZ-treated and untreated 
mice (control). Data represent the mean value ± SEM. 
2.5. Effect of pCEA-E on Cell Proliferation and Apoptosis 
To determine the effect of pCEA-E on cell proliferation and apoptosis, we examined Ki-67 expression 
using immunohistochemical staining and detected apoptotic cells using the TUNEL assay. Our results 
showed that Ki-67 expression significantly decreased (55.4% of expression relative to the control tissue) 
in tumors that received pCEA-E treatment, suggesting significant inhibition of cell proliferation  
(p < 0.05) (Figure 6). 
By contrast, the pCEA-LacZ treatment did not modulate Ki-67 expression, which was similar to the 
control group. On the other hand, analysis of the apoptosis-linked DNA fragmentation using a TUNEL 
assay showed similar staining between tumors treated with pCEA-E and the control tissue (Figure 7). 
  




Figure 6. Immunohistochemical staining of Ki-67 expression in mice bearing subcutaneous 
MC-38 tumors treated with pCEA-E. (A) Images of Ki-67 expression (green) and cell nuclei 
stained with DAPI (blue). Original magnification: 10×; and (B) Ki-67 histogram protein 
expression profiles. Ki-67 expression was lower in the pCEA-E-treated group than in  
the pCEA-LacZ and control groups (* p < 0.05). 
 
Figure 7. TUNEL assay in mice bearing subcutaneous MC-38 tumors. Images presenting 
apoptotic cells (red) and nuclei stained by DAPI (blue). pCEA-E treatment did not lead to an 
increased number of apoptotic cells in comparison with pCEA-LacZ or untreated tumors 
(control). Original magnification: 20×. 
3. Discussion 
Despite significant advances in the development of new therapies and improvements in traditional 
treatments for patients with advanced colon cancer, the prognosis and survival rate for these patients 
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remains poor. New gene therapy strategies are being developed to treat cancers, but to date have only 
demonstrated low levels of in vivo efficacy in terms of gene delivery and tumor specificity [17,28].  
The utility of tumor-specific promoters for gene targeted expression has been described in various 
cancers, such as melanoma, brain, lung, pancreas and colon [16,21,27,29,30]. Our study described the 
use of the CEA promoter to increase the colon cancer cell specificity of E gene expression and the 
subsequent tumor growth inhibition induced by expressing this cytotoxic gene. 
We have previously shown that E gene expression can induce apoptosis, dilated mitochondria with 
disrupted cristae, caspase-3 activation and the release of cytochrome C into the cytoplasm of some cancer 
cells [5,6,13]. In this study, we analyzed CEA activity through luciferase expression in several cell lines. 
We found the highest expression among all colon cancer cells in HTC-116 cell lines (33.4%) and the 
lowest in T-84 cells (3.49%); whereas normal CCD18co cells revealed practically undetectable levels of 
CEA. These results for CEA promoter activity are similar to those described by Gou et al. [31] and 
Dąbrowska et al. [32], who also observed a greater CEA promoter activity in colon cancer cell lines than 
in non-tumor cancer cell lines using a luciferase assay. 
Analysis of luciferase expression was correlated against the E gene’s inhibitor effect and revealed  
a decrease in the proliferation according to HTC-116 > MC-38 > T-84 > CCD18co. Furthermore, E gene 
transfection induced a significant and time-dependent decrease in HTC-116 and MC-38 cell growth, as 
has occurred in other cancer cells lines [6,13,14]. In fact, the greatest level of growth inhibition was 
found in both HTC-116 cells and MC-38 cells 72 h after transfection (48% and 36.6%, respectively).  
By contrast, low levels of growth inhibition were detected in T-84 and CCD18co cells (13.6% and 5.1% 
at 72 h after transfection, respectively). Other experiments using suicide genes under CEA transcriptional 
expression control corroborated a specific growth inhibition in cells with high levels of CEA expression. 
In fact, Zhang et al. [27] studied the effect of the CD suicide gene under CEA promoter control in the 
LoVo human colon cancer cell line (CEA-positive) in comparison to HeLa cells (a CEA-negative human 
adenocarcinoma cell line). Both cell lines were transfected with CEA-CD and treated with 5-FC for  
five days. HeLa cells transfected with CEA-CD did not sensitize the cytotoxicity caused by 5-FC, 
whereas CEA-CD LoVo cells showed a 72.7% growth inhibition. A similar study by Liu et al. [33] 
revealed a greater inhibition of growth (89.8%) in a CEA-positive human gastric cancer cell line 
(SGC7901 cells) than in a HeLa cell line (2%); in this case, both lines were treated with a double suicide 
gene system (TK and CD genes) under CEA control. 
To demonstrate the in vivo efficiency of our therapeutic system, we investigated the activity of  
the CEA promoter-E gene in mice bearing colon cancer tumors from MC-38 CEA-positive cells. 
Statistical evaluation of tumor growth rates obtained from mice treated with pCEA-E revealed  
a significant decrease (36%) of tumor volume in comparison to the control group. These results support 
the hypothesis that the E gene under CEA post-transcriptional control was able to reduce the proliferation 
rate of a tumor generated by CEA-positive cells. Studies by Zhang et al. [27] demonstrated a similar 
effect in LoVo mice xenografts treated with the CD gene under the CEA promoter. Liu et al. [33] studied 
a human xenograft gastric carcinoma during treatment with a double gene therapy system (CD and TK 
gene) for 36 days. A tumor growth inhibition of 54% was reported in treated tumors compared to control 
tumors. This greater decrease in tumor volume compared to our findings may be explained by the use of 
calcium phosphate nanoparticles (CPNP) that increase transfection efficiency and the use of a stable cell 
line to express therapeutic genes. Interestingly, analysis of Ki-67 showed a strong degree of expression 
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in the untreated and pCEA-LacZ groups (controls) in relation to tumors intratumorally treated with the  
pCEA-E vector. The decreased level of Ki-67 expression in pCEA-E genes is representative of the colon 
cancer cells’ loss of proliferative capacity. In fact, Okabe et al. [34] have demonstrated that the CEA 
promoter in an adenovirus expressing the TK gene was able to improve its antitumor activity in mice 
bearing colorectal tumors from RCM-1 CEA-positive cells and to reduce the number of liver metastases 
(after 42 days of treatment) in relation to an untreated group of mice. 
We previously reported the successful use of the E gene in cancer therapy. However, a lack of 
selective antitumor activity is its main limitation. The use of tumor-specific promoters of cytotoxic genes 
(but which have a low activity in normal cells) may direct therapeutic gene expression toward cancer 
cells. In this study, we demonstrated that the CEA promoter can induce E gene expression, which is 
selective of colon cancer cells, while the gene is practically unexpressed in normal cell lines. E gene 
expression under CEA control rapidly and efficiently inhibited cell growth in CEA-positive colon cancer 
cells, which, in turn, induced a significant decrease in the tumor volume of mice bearing such cancer 
cells. In addition, a decrease in Ki-67 tumor expression indicated a significant decrease in post-treatment 
cell proliferation. In conclusion, we propose that the CEA promoter provides a means of specifically 
directing E gene expression toward colon cancer cells in order to mediate suicide gene therapy. 
4. Experimental Section 
4.1. Cell Culture 
The human colon adenocarcinoma CACO-2, HT29, HCT-116, SW480, RKO and T-84 cell lines,  
the mice colon cancer MC-38 cell line (kindly provided by Jeffrey Schlom from Public Health Service, 
National Institutes of Health, Bethesda, MD, USA) and the normal human colon CCD18co cell line 
(Instrumentation Service Center, University of Granada, Granada, Spain) were used in this study. All cell 
types were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma, St. Louis, MO, USA), 
supplemented with 10% fetal bovine serum (FBS) and 1% streptomycin-penicillin (Sigma), under air 
containing 5% CO2 and in an incubator at 37 °C. 
4.2. Construction of Luciferase and E Expression Vectors 
CEA promoter from human genomic DNA was amplified by PCR using the primers: CTCGAGCCA 
TCCACCTTGCCGAAA and AAGCTTGCTGTCTGCTCTGTCCTC. XhoI and HindIII restriction sites 
were introduced into the forward and reverse primers, respectively. The CEA promoter fragment and pGL2 
vector (Promega Biotech Ibérica, Madrid, Spain) were digested with XhoI and HindIII restriction enzymes, 
and the CEA promoter fragment was finally cloned in the pGL2 vector (pGL2/CEA). We used a previously 
developed vector, pcDNA3.1/E (Rama et al., 2010), to construct the E expression vector under the control 
of the CEA promoter. Firstly, the CEA promoter was amplified by PCR from pGL2/CEA using the primers 
CAATTGCCATCCACCTTGCCGAAA and GAGCTCGCTGTCTGCTCTGTCCTC with MfeI and SacI 
restriction sites. Secondly, the pcDNA3.1/E CMV promoter was removed by digestion with MfeI and SacI. 
Finally, CEA was digested with the same restriction enzymes and ligated in place of the CMV  
promoter, thus generating pcDNA3.1/CEA/E (pCEA-E). pcDNA3.1/CEA/LacZ (pCEA-LacZ) was used 
as a control and generated from pcDNA3.1/LacZ using a method similar to the one for pCEA-E [13]. 
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Subcloning Efficiency™ DH5α™-competent E. coli cells (Qiagen, Barcelona, Spain) were transformed 
with the generated plasmids and their correct sequences confirmed by DNA sequencing. 
4.3. Luciferase Assay 
All transfections were performed using FUGENE6 reagent (Roche Diagnostic, Barcelona, Spain) 
according to the manufacturer’s instructions. Cells (7 × 103) were seeded into 96-well culture plates. 
After 24 h, the cells were co-transfected with 0.2 μg/well of luciferase reporter vectors (pGL2/CEA or pGL2) 
and 0.05 μg/well of CMV/Renilla vector as internal controls for normalization of the transcriptional 
activity of the reporter vectors (provided by Miguel Burgos of the Biotechnology Institute, Granada, 
Spain). Experiments were performed in three groups: cells transfected with pGL2/CEA and 
CMV/Renilla; cells transfected with pGL2 and CMV/Renilla; and untransfected cells (control).  
Forty-eight hours after transfection, luciferase activity was determined using the Dual-Glo Luciferase 
Assay System (Promega) according to the manufacturer’s instructions. The luminescence was measured 
in a luminometer (96 GloMax® microplate). The luciferase activity in each well was normalized  
to CMV/Renilla using the formula Ln = L/R (Ln: Normalized luciferase activity; L: Luciferase activity 
reading; R: Renilla activity reading). The Ln was further standardized according to the transcriptional 
activity of pGL2 using the formula of RLU = Ln/pGL3-basic (RLU: Relative luciferase unit).  
All transfections were performed in triplicate. 
4.4. In Vitro Proliferation Assay 
To determine the rate of proliferation, transfection was performed using FUGENE6 reagent  
(Roche Diagnostic) as described previously. Cells were seeded in 24-well plates (104 cells per well) to 
analyze proliferation. After 24 h, the cells were transfected with 1 μg/well of the respective vector 
(pCEA-E or pCEA-LacZ). Untransfected cells were used as a control. After 24, 48 and 72 h, MTT  
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 mg/mL) was added to each 
well (20 μL) and incubated for 4 h at 37 °C. Two hundred microliters of dimethylsulfoxide (DMSO)  
were then added to each well after the medium had been removed. Optical density was determined  
using a Titertek multiscan colorimeter (Flow Laboratories, Irvine, CA, USA) at 570 and 690 nm. Cells 
transfected with empty vectors were used as controls. 
4.5. Microscopic Analysis 
pcDNA3.1 provides a V5 epitope tag for efficient detection of recombinant proteins. Therefore,  
E protein expression was confirmed using the anti-V5-FITC antibody (Invitrogen, Madrid, Spain). The cells 
were grown on coverslips and transfected with pCEA-E and pCEA-LacZ. As above, untransfected cells 
were used as a control. After 24 h of transfection, cells were washed with PBS, fixed in 100% methanol 
at room temperature for 3 min, blocked with 10% bovine serum albumin/PBS for 20 min and then 
incubated with anti-V5-FIFC antibody diluted (1:500) in 1% bovine serum albumin/PBS. DAPI solution 
(100 nM) (Invitrogen, Madrid, Spain) was used for nuclear staining. The cells were then rinsed with 
PBS, mounted and visualized using fluorescent microscopy analysis (Nikon Eclipse Ti, Nikon 
Instruments Inc., Melville, NY, USA). V5 was excited at 488 nm and DAPI nuclear stain at 364 nm. 
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4.6. In Vivo Study 
Female C57BL/6 mice (Scientific Instrumentation Centre, University of Granada, Granada, Spain) 
were used in the in vivo studies. All mice (body weight: 25–30 g) were kept in a laminar airflow cabinet 
located in an ambient-controlled room (37.0 ± 0.5 °C and a relative humidity of 40%–70%) and subjected 
to a 12-h day/night cycle under specific pathogen-free conditions. All studies were approved by the 
Ethics Committee of the Medical School at the University of Granada and complied with international 
standards (European Communities Council Directive 86/609). Tumors were induced by subcutaneous 
injection of 7 × 105 MC-38 cells in 200 μL of PBS into the left flanks of mice. Tumors were allowed to 
grow to 75 mm3 (a minimal size for ideal intratumoral injection) before starting intratumoral treatment. 
Mice were randomly assigned to the following groups: treated with pCEA-E, treated with pCEA-LacZ 
and untreated (control). In vivo JetPEI (Polyplus-transfection Inc., New York, NY, USA) was used as  
a transfection enhancer reagent according to the manufacturer’s instructions. PEI/DNA complexes  
with a ratio of 1:6 were formed for 15 μg DNA/50 μL 10% glucose plus 1.8 μL in vivo-JetPEI/50 μL 10% 
glucose. Each mouse received intratumoral injections every three days, up to a maximum total of six 
administrations. Mice weights and deaths were recorded throughout this period. Tumor volumes (V, mm3) 
were estimated by using a digital caliper to measure the largest diameter “a” and the second largest 
diameter “b” perpendicular to “a”, then calculating the volume from, V = ab2 × π/6. 
4.7. Histological Studies 
Tumors were cryopreserved at −80 °C then cut into 15 μm-thick cryostat sections, collected on  
gelatin-coated slides and stored at −20 °C until used. The presence of apoptotic cells within the tumor 
sections was evaluated after 20 min of fixation with 4% paraformaldehyde at room temperature using 
the TUNEL technique with the In Situ Cell Death Detection Kit TMR red (Roche, Mannheim, Germany) 
according to the manufacturer’s recommendations. Cell nuclei were counterstained with DAPI and 
fluorescence images captured using a Nikon eclipse 50i microscope. Sections were probed with  
Ki-67(M-19) antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany) in order to evaluate 
proliferation. Tissue sections were fixed for 20 min with 4% paraformaldehyde at room temperature. 
The sections were then washed with PBS and blocked for 1 h with donkey serum before being incubated 
for 1 h at room temperature with the primary antibody (1:100). The sections were then washed with  
PBS and incubated at room temperature with an Alexa 488 anti-donkey secondary antibody (1:500) 
(Invitrogen, Madrid, Spain) for 1 h. Cell nuclei were again counterstained with DAPI and fluorescence 
images captured with a Nikon eclipse 50i microscope. Representatively, stained areas on all slides were 
digitally imaged, and TUNEL and Ki-67 protein expressions were quantified using ImageJ software plugins. 
4.8. Statistical Analysis 
All of the results were represented as the mean ± standard deviation (SEM). Statistical analysis was 
performed using the Student’s t-test (SPSS version 15, SPSS, Chicago, IL, USA). The probability of 
mice survival was determined by the Kaplan–Meier method, and the log-rank test was used to compare 
the fraction of surviving mice between groups (α = 0.05). Data with p < 0.05 and p < 0.001 were 
considered as significant and very significant, respectively. 




New gene therapy strategies are being developed to treat cancers. The use of tumor-specific promoters 
are being developed may help to direct the expression of therapeutic genes so they act against specific 
cancer cells. We have proved that carcinoma embryonic antigen is an excellent tumor-specific promoter 
to direct E gene expression towards colon cancer cells but not to normal colon cells, inducing cell  
growth inhibition, Ki-67 expression reduced and decrease of tumor volume. We propose the system  
of the E gene under CEA post-transcriptional as a novel gene therapy strategy for the treatment of  
colorectal cancer. 
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